UK-based AstraZeneca, a global biopharmaceutical company, has announced plans to build a US$1.5bn manufacturing facility in Singapore for antibody drug conjugates (ADCs), enhancing global supply of its ADC portfolio. ADCs…
Singapore: AstraZeneca unveils plans to build ADC manufacturing facility
…
…






